150 related articles for article (PubMed ID: 34973391)
1. TRIM29 regulates the SETBP1/SET/PP2A axis via transcription factor VEZF1 to promote progression of ovarian cancer.
Qiao HY; Zhang Q; Wang JM; Jiang JY; Huyan LY; Yan J; Li C; Wang HQ
Cancer Lett; 2022 Mar; 529():85-99. PubMed ID: 34973391
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Potential Alterations Affecting SETBP1 as a Novel Contributing Mechanism to Inhibit PP2A in Colorectal Cancer Patients.
Torrejón B; Cristóbal I; Caramés C; Prieto-Potín I; Chamizo C; Santos A; Sanz-Alvarez M; Serna-Blasco R; Luque M; Madoz-Gúrpide J; Rojo F; García-Foncillas J
World J Surg; 2018 Nov; 42(11):3771-3778. PubMed ID: 29796729
[TBL] [Abstract][Full Text] [Related]
3. m6A-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells.
Hao L; Wang JM; Liu BQ; Yan J; Li C; Jiang JY; Zhao FY; Qiao HY; Wang HQ
Biochim Biophys Acta Mol Cell Res; 2021 Jan; 1868(1):118878. PubMed ID: 33011193
[TBL] [Abstract][Full Text] [Related]
4. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
5. Loss of TRIM29 Alters Keratin Distribution to Promote Cell Invasion in Squamous Cell Carcinoma.
Yanagi T; Watanabe M; Hata H; Kitamura S; Imafuku K; Yanagi H; Homma A; Wang L; Takahashi H; Shimizu H; Hatakeyama S
Cancer Res; 2018 Dec; 78(24):6795-6806. PubMed ID: 30389700
[TBL] [Abstract][Full Text] [Related]
6. The protein level of the tumour-promoting factor SET is regulated by cell density.
Kohyanagi N; Kitamura N; Tanaka K; Mizuno T; Fujiwara N; Ohama T; Sato K
J Biochem; 2022 Mar; 171(3):295-303. PubMed ID: 35076073
[TBL] [Abstract][Full Text] [Related]
7. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.
Piazza R; Valletta S; Winkelmann N; Redaelli S; Spinelli R; Pirola A; Antolini L; Mologni L; Donadoni C; Papaemmanuil E; Schnittger S; Kim DW; Boultwood J; Rossi F; Gaipa G; De Martini GP; di Celle PF; Jang HG; Fantin V; Bignell GR; Magistroni V; Haferlach T; Pogliani EM; Campbell PJ; Chase AJ; Tapper WJ; Cross NC; Gambacorti-Passerini C
Nat Genet; 2013 Jan; 45(1):18-24. PubMed ID: 23222956
[TBL] [Abstract][Full Text] [Related]
8. TRIM29 promotes progression of thyroid carcinoma via activating P13K/AKT signaling pathway.
Xu J; Li Z; Su Q; Zhao J; Ma J
Oncol Rep; 2017 Mar; 37(3):1555-1564. PubMed ID: 28098872
[TBL] [Abstract][Full Text] [Related]
9. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
10. TRIM29 regulates the p63-mediated pathway in cervical cancer cells.
Masuda Y; Takahashi H; Hatakeyama S
Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2296-305. PubMed ID: 26071105
[TBL] [Abstract][Full Text] [Related]
11. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.
Farrell AS; Allen-Petersen B; Daniel CJ; Wang X; Wang Z; Rodriguez S; Impey S; Oddo J; Vitek MP; Lopez C; Christensen DJ; Sheppard B; Sears RC
Mol Cancer Res; 2014 Jun; 12(6):924-39. PubMed ID: 24667985
[TBL] [Abstract][Full Text] [Related]
12. Tripartite motif-containing 29 (TRIM29) is a novel marker for lymph node metastasis in gastric cancer.
Kosaka Y; Inoue H; Ohmachi T; Yokoe T; Matsumoto T; Mimori K; Tanaka F; Watanabe M; Mori M
Ann Surg Oncol; 2007 Sep; 14(9):2543-9. PubMed ID: 17597343
[TBL] [Abstract][Full Text] [Related]
13. RNA interference against TRIM29 inhibits migration and invasion of colorectal cancer cells.
Xu W; Xu B; Yao Y; Yu X; Cao H; Zhang J; Liu J; Sheng H
Oncol Rep; 2016 Sep; 36(3):1411-8. PubMed ID: 27430345
[TBL] [Abstract][Full Text] [Related]
14. Loss of TRIM29 suppresses cancer stem cell-like characteristics of PDACs via accelerating ISG15 degradation.
Sun J; Yan J; Qiao HY; Zhao FY; Li C; Jiang JY; Liu BQ; Meng XN; Wang HQ
Oncogene; 2020 Jan; 39(3):546-559. PubMed ID: 31501523
[TBL] [Abstract][Full Text] [Related]
15. TRIM29 functions as a tumor suppressor in nontumorigenic breast cells and invasive ER+ breast cancer.
Liu J; Welm B; Boucher KM; Ebbert MT; Bernard PS
Am J Pathol; 2012 Feb; 180(2):839-47. PubMed ID: 22138580
[TBL] [Abstract][Full Text] [Related]
16. The interaction of SET and protein phosphatase 2A as target for cancer therapy.
Dacol EC; Wang S; Chen Y; Lepique AP
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188578. PubMed ID: 34116173
[TBL] [Abstract][Full Text] [Related]
17. TRIM29 overexpression is associated with poor prognosis and promotes tumor progression by activating Wnt/β-catenin pathway in cervical cancer.
Xu R; Hu J; Zhang T; Jiang C; Wang HY
Oncotarget; 2016 May; 7(19):28579-91. PubMed ID: 27081037
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
[TBL] [Abstract][Full Text] [Related]
19. TRIM29 functions as an oncogene in gastric cancer and is regulated by miR-185.
Qiu F; Xiong JP; Deng J; Xiang XJ
Int J Clin Exp Pathol; 2015; 8(5):5053-61. PubMed ID: 26191199
[TBL] [Abstract][Full Text] [Related]
20. TRIM29 promotes antitumor immunity through enhancing IGF2BP1 ubiquitination and subsequent PD-L1 downregulation in gastric cancer.
Jiang T; Xia Y; Li Y; Lu C; Lin J; Shen Y; Lv J; Xie L; Gu C; Xu Z; Wang L
Cancer Lett; 2024 Jan; 581():216510. PubMed ID: 38029830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
